文献速递心脑血管急症重症综合管理与镇静镇痛

雄激素调节药物与ST段抬高型心肌梗死后的严重并发症

Androgen-Modulating Drugs and Severe Complications After ST-Elevation Myocardial Infarction.
PubMed 文献 · JAMA Netw Open · 2026-08-03
一句话结论在PCI治疗的男性STEMI患者中,使用5α还原酶抑制剂与严重并发症风险降低相关(OR 0.80),而雄激素剥夺治疗未见显著关联(OR 1.10)。

瑞典全国登记队列研究纳入2006年1月至2022年12月首次因STEMI接受PCI治疗的35至84岁男性,采用倾向评分匹配比较使用5α还原酶抑制剂或雄激素剥夺治疗者与未治疗对照。主要终点为30天内死亡与严重院内并发症的复合终点。5α还原酶抑制剂组1305例匹配6463例对照,严重并发症风险较低(OR 0.80;95%CI 0.69-0.93);雄激素剥夺治疗组358例匹配1774例对照,未见显著关联(OR 1.10;95%CI 0.83-1.45)。作者认为结果需进一步研究雄激素及影响雄激素水平的药物在STEMI急性期的作用。

要点

  • 男性STEMI接受PCI后,使用5α还原酶抑制剂与严重并发症风险降低相关(OR 0.80;95%CI 0.69-0.93)。
  • 雄激素剥夺治疗与严重并发症无显著关联(OR 1.10;95%CI 0.83-1.45)。
  • 主要终点为30天内死亡与严重院内并发症的复合终点,包括心脏骤停与复苏、II或III度房室传导阻滞、心源性休克、新发心房颤动或扑动、左心室功能严重抑制或机械并发症。
  • 研究为瑞典全国登记队列,5α还原酶抑制剂组1305例匹配6463例对照,雄激素剥夺治疗组358例匹配1774例对照。

适用人群与场景

  • 2006年1月至2022年12月瑞典全国登记中首次因STEMI接受PCI治疗的35至84岁男性。

研究设计与关键结果

  • 研究类型:瑞典全国登记队列研究,采用倾向评分匹配。
  • 5α还原酶抑制剂组1305例(平均[SD]年龄74.2[6.7]岁)匹配6463例对照,严重并发症风险较低(OR 0.80;95%CI 0.69-0.93)。
  • 雄激素剥夺治疗组358例(平均[SD]年龄76.2[6.2]岁)匹配1774例对照,严重并发症无显著关联(OR 1.10;95%CI 0.83-1.45)。
  • 主要终点为30天内死亡与严重院内并发症的复合终点,严重院内并发症包括心脏骤停与复苏、II或III度房室传导阻滞、心源性休克、新发心房颤动或扑动、左心室功能严重抑制或机械并发症。

证据类型、等级与局限

  • 证据类型:全国登记队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,这些结果需进一步研究雄激素及影响雄激素水平的药物在STEMI急性期的作用。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Male sex and endogenous testosterone have been shown to exacerbate neutrophilia and cardiac injury in myocardial infarction (MI), raising questions about protective actions of androgen-modulating drugs in acute ST-elevation MI (STEMI).

OBJECTIVE: To determine whether the use of 5-alpha reductase inhibitors (5αRIs) or androgen deprivation therapy (ADT), drugs that lower androgen actions, is associated with a reduced frequency of severe complications after percutaneous coronary intervention (PCI)-treated STEMI in men.

DESIGN, SETTING, AND PARTICIPANTS: Nationwide, registry-based cohort study of men aged 35 to 84 years with first-time STEMI treated with PCI from January 2006 to December 2022 in Sweden. Propensity score matching was used to match men treated with 5αRIs or ADT with untreated control patients. The primary outcome was a composite of mortality within 30 days and severe in-hospital complications. Data were analyzed in June 2026.

MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of mortality within 30 days and severe in-hospital complications (any of: cardiac arrest and resucitatation, atrioventricular block stage II or III, cardiogenic schock, new-onset atrial fibrillation or flutter, severely depressed left ventricular function, or mechanical complication). Odds ratios were calculated using conditional logistic regression.

RESULTS: In this study of men with PCI-treated STEMI, 1305 men treated with 5αRI (mean [SD] age, 74.2 [6.7] years) were matched to 6463 control patients, and 358 men treated with ADT (mean [SD] age, 76.2 [6.2] years) were matched to 1774 control patients. The odds of experiencing a severe complication were lower in men treated with 5αRIs (odds ratio [OR], 0.80; 95% CI, 0.69-0.93). No significant association was observed for men treated with ADT compared with their matched control patients (OR, 1.10; 95% CI, 0.83-1.45).

CONCLUSIONS AND RELEVANCE: In this cohort study of men with PCI-treated STEMI, use of 5αRI but not ADT was associated with a lower risk of severe complications. These results warrant further research into the role of androgens and drugs that affect androgen levels in the acute phase of STEMI.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Colldén H, Lundberg CE, Björck L, et al. Androgen-Modulating Drugs and Severe Complications After ST-Elevation Myocardial Infarction. JAMA Netw Open. 2026. PMID: 42640637. doi:10.1001/jamanetworkopen.2026.30774

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。